Compare COHU & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | TSHA |
|---|---|---|
| Founded | 1947 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | COHU | TSHA |
|---|---|---|
| Price | $47.96 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $70.88 | $13.00 |
| AVG Volume (30 Days) | 973.1K | ★ 3.8M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,956,000.00 | $9,773,000.00 |
| Revenue This Year | $35.26 | N/A |
| Revenue Next Year | $25.65 | $1,023.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.74 | ★ 17.28 |
| 52 Week Low | $21.10 | $3.46 |
| 52 Week High | $75.72 | $7.30 |
| Indicator | COHU | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 35.37 | 36.87 |
| Support Level | $42.68 | $3.46 |
| Resistance Level | $58.35 | $4.72 |
| Average True Range (ATR) | 3.63 | 0.27 |
| MACD | -2.41 | 0.03 |
| Stochastic Oscillator | 8.66 | 40.81 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.